Background. Few data on the effect of human papillomavirus (HPV) infection on human immunodeficiency virus (HIV) acquisition are available.
important component of HIV prevention research. Although several sexually transmitted infections have been shown to be associated with HIV, few data on the possible effect of human papillomavirus (HPV) infection on HIV acquisition exist. Clear evidence of an association between HPV and the risk of HIV infection would suggest a new possible intervention for HIV prevention; unlike efforts to develop an effective HIV prophylactic vaccine, HPV vaccines have shown tremendous promise for the prevention of persistent HPV infections and HPV-associated clinical outcomes in both women and men [1, 2] .
No ecological or observational studies comparing the risk of incident HIV infection between HPV-positive and HPV-negative heterosexual men have been published, to our knowledge. One observational study conducted among 1409 HIV-seronegative men who have sex with men in San Francisco found that anal infection with at least 2 types of HPV was significantly associated with a higher risk of HIV seroconversion, although multivariate results did not reach statistical significance for men with single-type anal HPV infection and were not adjusted for herpes simplex virus type 2 (HSV-2) serostatus or the presence of other sexually transmitted infections [3] .
We have previously reported that circumcision statistically significantly reduced the risk of HIV acquisition in a randomized controlled trial of male circumcision in Kisumu, Kenya [4] . Here, we report results from the same cohort on the relative risk of HIV incidence in HPV DNA-positive men compared with HPV-negative men at their baseline visit, controlling for circumcision status and other potential confounders, to better understand the effect of HPV infection on the incidence of HIV.
METHODS
A randomized controlled trial was conducted between February 2002 and December 2006 in men aged 18-24 years in Kisumu, as described elsewhere [4] . The primary aim of the trial was to determine the effectiveness of male circumcision in reducing the incidence of HIV infection. Inclusion criteria included being uncircumcised, being seronegative for HIV, being sexually active, and having a hemoglobin level of 90 g/L or more.
The present analysis included men enrolled in the trial who consented to the collection of an exfoliated penile cell sample and its shipment overseas for HPV DNA testing (Figure 1) . A total of 6686 men were screened, and 2784 were randomized to the trial [4] . Of these, 2228 consented to this ancillary study of HPV infection and had risk factor data collected at the baseline visit. The present analysis included 2168 of these men; 3 men were excluded because they were HIV positive at baseline, and 57 men were excluded because they were randomized to be circumcised but did not undergo surgery within the first 2 weeks of the trial. The original trial randomized consenting participants to either the intervention (circumcision) arm or the control (delayed circumcision) arm and included 24 months of follow-up. Follow-up was extended for the last 1740 men enrolled, and 1550 men entered extended follow-up. The present analysis reports follow-up to 42 months. The study protocol was reviewed and approved by the Institutional Review Boards of the University of Illinois at Chicago, the University of Manitoba, the University of Nairobi, the University of North Carolina, and the Vrije Universiteit University Medical Center.
Questionnaire, clinical examination, and specimen collection. After providing informed consent, participants were administered a standardized questionnaire on sociodemographic characteristics and sexual behavior by a trained male interviewer. Exfoliated penile cells were collected for HPV DNA detection from 2 anatomical sites, the glans/coronal sulcus and the shaft, using techniques described elsewhere [5] .
HPV DNA laboratory testing. The HPV DNA testing results presented here are for participating uncircumcised men at the baseline study visit. DNA was isolated from exfoliated penile cell samples by means of the NucleoSpin 96 Tissue kit (Macherey-Nagel) and a Microlab Star robotic system (Hamilton, Germany), in accordance with the manufacturers' instructions. The presence of human DNA was evaluated by bglobin-specific polymerase chain reaction (PCR), followed by agarose gel electrophoresis. HPV DNA positivity was assessed by GP5+/6+ PCR, followed by hybridization of PCR products using an enzyme immunoassay readout with 2 HPV oligoprobe cocktail probes that together detect 44 HPV types: 6, 11, 16, 18, 26, 30-35, 39, 40, 42-45, 51-59, 61, 64, 66-70, 71 (equivalent to CP8061), 72, 73, 81 (equivalent to CP8304), 82 (IS39 and MM4 subtypes), 83 (equivalent to MM7), 84 (equivalent to MM8), cand85, 86, cand89 (equivalent to CP6108), and JC9710. Subsequent HPV genotyping was performed by reverse line blot hybridization of PCR products, as described elsewhere [6] . Primers and probe sequences, as well as cycling and staining conditions, have been detailed elsewhere [6, 7] .
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68 were classified as high-risk (carcinogenic) HPV types. HPV infections with multiple HPV types were considered high risk if 1 or more high-risk HPV types were detected. Low-risk types included all other HPV types. HPV types detected by enzyme immunoassay but not by reverse line blot genotyping were designated as HPV X, indicating a type, subtype, or variant not detectable with probes used for reverse line blot hybridization. Urine samples from the baseline visit were tested for Neisseria gonorrhoeae and Chlamydia trachomatis infections by PCR-based methods (Roche Diagnostics), and serum was tested for HSV-2 antibodies by a type-specific enzyme-linked immunosorbent assay (ELISA) (Kalon).
Circumcision procedure. Participants who met the study criteria were randomly assigned to either the intervention (cir-cumcision) arm [8] Results were available within 1 week. Participants were deemed to be confirmed positive if results were positive for both HIV ELISAs. Participants with 2 negative ELISA results were considered negative; discordant ELISA results were considered indeterminate, and the participant was asked to return for additional testing 1-6 months later, depending on the visit. For purposes of determining HIV serostatus for analysis of study data, blood specimens from all participants who tested positive by at least 1 rapid test and 1 ELISA were sent to the Health Canada National HIV Reference Laboratory (Ottawa, Canada) for confirmatory testing by line immunoassay (Inno-Lia HIV 1/2; Immunogenetics). Specimens that were indeterminate by line immunoassay were tested by PCR at Health Canada or the Fred Hutchinson Cancer Research Center (Seattle, Washington), with the PCR result deemed to be definitive. Any participant confirmed to be positive at a follow-up visit had his baseline specimen tested at the Health Canada laboratory to ascertain HIV serostatus at enrollment. Participants who had a confirmed positive test result at the month 3 follow-up visit had their month 1 specimen tested by PCR. The HIV seroconversion visit was judged to be the first visit at which the participant had at least 1 positive HIV rapid test result and was confirmed to be HIV positive at the same or a subsequent visit according to the above-described procedure.
Statistical methods. Associations between HPV infection and baseline characteristics were assessed using the Pearson x 2 test or the Fisher exact test for categorical variables and the Wilcoxon rank sum test for continuous variables. The McNemar test was used to assess differences in the prevalence of HPV between the 2 anatomical sampling sites. The KaplanMeier method was used to estimate the cumulative incidence of HIV seroconversion over time. Differences in HIV seroconversion distributions were summarized using the log rank test. Hazard ratios (HRs) for the effect of HPV infection at baseline on HIV seroconversion and corresponding 95% confidence intervals (CIs) were estimated via Cox proportional hazards models, using an exact method to adjust for ties. Multivariate proportional hazards models included circumcision status as well as risk factors with significant marginal associations ( ) P ! .10 with HIV or variables believed a priori to be potential confounders. Variables not significant at the .10 level in multivariate models were eliminated sequentially in order of P value magnitude. The Akaike information criterion was used to compare nonnested models [9] . All P values reported are 2-sided.
Unless otherwise noted, men randomized to the control arm who became circumcised before HIV seroconversion were right-censored at their last visit before circumcision. Analyses were also performed with circumcision as a time-varying covariate. Sensitivity analyses were conducted using data only from the original 24-month follow-up period, because only a subset of the original participants were observed at 42 months and uncircumcised men could self-select to be circumcised or remain uncircumcised after 24 months.
RESULTS
Of 2168 men included in the analyses, 1089 (50%) had HPV DNA detected in either the glans/coronal sulcus or shaft specimens at baseline. The prevalence of HPV was significantly higher in the glans/coronal sulcus specimens than in the shaft specimens (46% vs 18%;
). Of the 1089 men infected P ! .001 with HPV, 991 (91%) had HPV DNA detected in the glans/ coronal sulcus specimen. Baseline characteristics significantly associated with HPV infection in the glans/coronal sulcus or shaft included the following: less than secondary educational level ( ); salaried or self-employment ( ); less P р .001 P p .001 than daily bathing ( ); presence of genital warts ( P p .01 P p ); HSV-2 seropositivity ( ); gonorrhea ( ); .04 P p .02 P p .02 chlamydia ( ); no use of condom with last partner P p .05 ( ); and greater reported lifetime number of female sex P p .001 partners ( ) (Table 1) . P p .04 Figure 2 shows Kaplan-Meier estimates of the cumulative incidence of HIV seroconversion stratified by baseline HPV and circumcision status. The 42-month cumulative incidence of HIV was 5.3% (95% CI, 3.4%-7.2%) among men with HPV detected in the glans/coronal sulcus or shaft, versus 4.0% (95% CI, 1.9%-6.1%) among HPV-negative men (
). Simi-P p .04 larly, there was greater risk of HIV seroconversion by 42 months among men with HPV-positive glans/coronal sulcus specimens, compared with that among men with HPV-negative glans/coronal sulcus specimens (5.8% [95% CI, 3.6%-7.9%] vs 3.7% [95% CI, 1.8%-5.6%];
). P p .01 Estimated HRs for different categories of baseline HPV positivity are presented in Table 2 . For each categorization of HPV infection, adjusted HR estimates were obtained from multivariate proportional hazards models that included circumcision status, age, employment status, and HSV-2 infection. Gonorrhea was marginally associated with the risk of HIV infection but was not significant at the .10 level in any multivariate model. Other variables in Table 1 were not associated with HIV risk in both unadjusted and adjusted analyses. Genital warts were not considered in the multivariate models because they were present at baseline in only 12 men (!1%). The adjusted hazard of HIV infection was 1.6 (95% CI, 1.0-2.7) times higher among men with HPV in either the glans/coronal sulcus or shaft, compared with HPV-negative men (Table 2) . Similarly, the adjusted HR estimate for men with HPV-positive glans/ coronal sulcus specimens was higher (1.8 [95% CI, 1.1-2.9]), compared with men without HPV in the glans/coronal sulcus. HIV infection rates did not significantly differ between men infected with multiple HPV types and those infected with single HPV types ( ) or between men infected with high-risk P p .37 HPV types and those infected with low-risk HPV types (P p ). With respect to HPV types included in current-generation .59 prophylactic vaccines, the hazard of HIV infection among men infected with HPV-16 or HPV-18 was significantly greater than that among HPV-negative men but differed only marginally from that among men infected with other HPV types (P p ) ( Table 2 and Figure 3 ). The hazard of HIV infection among .07 individuals infected with HPV-16, HPV-18, HPV-6, or HPV-11 was significantly greater than that among HPV-negative individuals but did not differ significantly from that among HPV- positive individuals not infected with type 16, 18, 6, or 11 ( ). There was no evidence of an interaction between P p .20 the effects of circumcision status and HPV for any categorization of HPV infection (P values ranged from .11 to .93) ( Table  2) , indicating a lack of effect modification.
Comparison of the different multivariate models by the Akaike information criterion (Table 2) showed that categorization by HPV positivity in the glans/coronal sulcus provided the best fit. For this model (Table 3) , higher rates of HIV seroconversion were associated with being younger, being employed, and being HSV-2 seropositive. There was no evidence of an interaction between HSV-2 and HPV infection in the glans/coronal sulcus and the risk of HIV acquisition (P p ). The HR estimate and corresponding P value for HPV were .43 virtually the same regardless of whether HSV-2 infection was included in or excluded from the multivariate model. Multivariate analyses stratifying on circumcision status (data not shown) yielded results that were nearly identical to those obtained with circumcision included as a covariate. The multivariate model using circumcision as a time-dependent covariate also yielded results similar to those given in Table 3 , with an adjusted HR estimate for HPV in the glans/coronal sulcus of 2.0 (95% CI, 1.2-3.3) and a corresponding P value of .008. Restricting analyses to men with b-globin-positive specimens gave results similar to those of the analyses that included all participants described above. For instance, of the 2168 men included in the main analysis, 1225 (57%) had b-globin-positive specimens from the glans/coronal sulcus. Fitting the final model described in Table 3 to data from these 1225 men only, the adjusted hazard of HIV infection was 2.3 (95% CI, 1.1-4.8) times higher in men with HPV in the glans/coronal sulcus, compared with men without HPV in the glans/coronal sulcus ( ) . P p .03 Similar results were also obtained when the final multivariate model was fit to data limited to the first 24 months of followup. The estimated adjusted HR of HIV infection in men with HPV-positive glans/coronal sulcus specimens was 1.7 (95% CI, 1.0-3.2;
). Age and employment also remained asso-P p .05 ciated with the risk of HIV infection ( and , P p .07 P p .006 respectively), although HSV-2 infection was no longer significant ( ). P p .34 
DISCUSSION
Among 2168 young men in Kenya, HPV infection was independently associated with an increased risk of HIV acquisition over 42 months of follow-up. Observed associations were largely due to HPV infection in the glans/coronal sulcus. Effect estimates were similar before and after adjustment for HSV-2 serostatus, gonorrhea, chlamydia, and other possible confounders. HIV risk was not associated with the presence of multipletype HPV infections or the presence of high-risk HPV types. HR estimates of HIV acquisition associated with baseline HPV glans/coronal sulcus positivity were virtually identical to those associated with baseline HSV-2 seropositivity. Associations between HSV-2 seropositivity and an increased risk of HIV infection have been observed in previous studies, with similar magnitudes of increased risk [10] . With adjustment for HSV-2 serostatus, the observed increased risk of HIV infection among HPV-positive men was less likely to be due to residual confounding of sexual behavior, although this possibility cannot completely be ruled out. Within this population of young men at a high risk for HIV acquisition in Kenya, HPV infection was very common (50%), so preventing HPV infection could potentially be another tool for HIV prevention.
In terms of biological plausibility, HPV infection, unlike many other sexually transmitted infections, is localized to epithelial cells, thus limiting exposure of the virus to the immune system [11] . Although HPV infection alone is not generally characterized by the induction of notable inflammatory responses, an up-regulation of T cells has been observed during the clearance of genital warts [12] and cervical lesions in women [13, 14] , thus resulting in a higher number of HIV-susceptible cells. Alternatively, HPV-associated flat lesions and penile intraepithelial neoplasia in men are characterized by inflammatory infiltrates with hyperemic blood vessels, which may potentially enhance susceptibility to HIV infection by creating portals of HIV entry, analogous to genital tissue microtrauma [15, 16] . HPV and HPV-associated genital lesions may also induce the local production of specific cytokines (ie, macrophage inflammatory protein 3 and interleukin 8), which may in turn increase HIV susceptibility [17] . One limitation of the present study is that associations between HIV and HPV were based on ascertainment of HPV infection rather than the detection of HPV-associated clinical outcomes, because HPV-associated flat penile lesions [16] were not ascertained at the baseline visit and the observed prevalence of genital warts was quite low (!1%). The strengths of our study include a relatively large sample size, the ascertainment of a broad range of HPV types using the GP5+/6+ HPV DNA detection assay, and the comprehensive laboratory ascertainment of incident HIV acquisition. To our knowledge, only one other study has published prospective data on an increased risk of HIV infection among HPV-positive individuals [3] ; however, that study did not include heterosexual men, nor did it control for HSV-2 seropositivity. Another study conducted among 1638 heterosexual men participating in a randomized clinical trial of male circumcision in South Africa reported a higher incidence of HIV infection among men with HPV-positive results for urethral sampling, compared with men with HPV-negative results [18] . However, HPV DNA was ascertained at the last study visit, and some cases of HIV infection may have preceded acquisition of HPV infection; thus, the temporal associations between HPV and HIV risk could not be established in that study. Some caution is needed with respect to interpretation of our results extending beyond the 24 months of the trial, because only a subset of the original participants were observed; uncircumcised men could self-select to be circumcised or remain uncircumcised, and there were only a moderate number of HIV infections after 24 months. Our main study findings were similar, however, when the data were restricted to 24 months. Furthermore, sensitivity analyses of the effect of baseline HPV DNA status on HIV risk presented in Table 2 among stratified, nonoverlapping HPV subgroups for comparison (eg, HPV positive for type 16, 18, 6, or 11) are limited, because of relatively small sample sizes. For example, we were not able to reliably examine the effect of HPV positivity in the penile shaft separately from that of the glans/coronal sulcus, given that most men (∼90%) who were positive in the glans/coronal sulcus specimen were also positive in the shaft specimen. Although our results were based on a randomized clinical trial and none of the sexual behavior variables given in Table 1 were found to be associated with the risk of HIV infection, these analyses were limited to a cross-sectional assessment of HPV DNA status, HSV-2 seropositivity, and sexual behavior at baseline, rather than a longitudinal assessment of the effect of these factors on HIV acquisition over study follow-up. Finally, we classified HPV types as high risk on the basis of their association with invasive cervical cancer among women, although it is currently not clear whether such a classification might be important in men.
If our results are confirmed by others, they would suggest that, in addition to male circumcision, vaccinating against HPV could be an effective way to prevent HIV infection. Two prophylactic HPV vaccines have the potential to prevent invasive cervical cancer and precancerous disease attributable to oncogenic types HPV-16 and HPV-18 [19, 20] . The quadrivalent vaccine can also prevent low-risk HPV-6 and HPV-11, which cause genital warts [19] . HR estimates from our analysis suggest that prophylactic vaccines that provide protection against the oncogenic types HPV-16 and HPV-18 may reduce the hazard of HIV infection by half, assuming that vaccination prevents infections with HPV-16 or HPV-18 when administered to young men before first sexual intercourse. In uncircumcised men, HPV vaccination and circumcision could lead to even greater reductions: for instance, in our study the estimated 24-month cumulative incidence of HIV infection among uncircumcised men infected with HPV-16 or HPV-18 was 3.9% (95% CI, 0.5%-7.2%), compared with only 0.8% (95% CI, 0.2-1.4%) among circumcised men without HPV-16 and HPV-18 infection (Figure 3 ). Although community-based randomized controlled trials have investigated the effect of the prevention of bacterial sexually transmitted infections on the incidence of HIV infection [21, 22] , no trials have examined the effectiveness of preventing HPV infection. Our results warrant the conduct of a randomized controlled trial to determine whether prophylactic HPV vaccination reduces the acquisition of HIV infection.
